Cost-effectiveness of trastuzumab as adjuvant therapy for early breast cancer: A systematic review

Annals of Pharmacotherapy

Volumn 43, Issue 2, 2009, Pages 296-303

  Chan, Agnes L F ^a,b   Leung, Henry W C ^b   Lu, Chin Li ^b   Lin, Shun Jin ^a,b  

^a KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^b CHI MEI MEDICAL CENTER   (Taiwan)

Author keywords

Cost effectiveness; Quality adjusted life year; Trastuzumab

Indexed keywords

CYCLOPHOSPHAMIDE; EPIRUBICIN; FLUOROURACIL; TRASTUZUMAB;

BREAST CANCER; CANCER ADJUVANT THERAPY; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; EARLY CANCER; ECONOMIC EVALUATION; FUNDING; HUMAN; MASTECTOMY; ONCOGENE NEU; PARTIAL MASTECTOMY; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; REVIEW; SYSTEMATIC REVIEW;

ANTIBODIES, MONOCLONAL; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; CLINICAL TRIALS AS TOPIC; COST-BENEFIT ANALYSIS; FEMALE; HUMANS; MODELS, ECONOMIC; QUALITY-ADJUSTED LIFE YEARS; RESEARCH DESIGN; TIME FACTORS;

EID: 60349087780     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1L504     Document Type: Review

References (35)

1. Breast cancer: statistics on incidence, survival and screening. www.imaginis.com/breasthealth/statistics.asp (accessed 2008 Jul 17).
2. Cancer Register System, Bureau of Health Promotion, Department of Health, ROC http://crs.cph.ntu.edu.tw/crs-c/index-c.htm (accessed 2008 Jul 17).
3. Cheng SH, Tsou MH, Liu MC, et al. Unique features of breast cancer in Taiwan; breast cancer research and treatment. Breast Cancer Res Treat 2000;63:213-23 Epub 11 Sept 2007. DOI 10.1345/aph.1K089
4. Three big killers of Taiwan workers: cancer, accident, liver disease (11/22/2007). The Institute of Occupational Safety and Health. http://newwww.iosh.gov.tw/English/Publish.aspx?cnid=125&P=359 (accessed 2008 Jul 17).
5. Nistor A, Watson PH, Pettigrew N, Tahiti K, Dawson A, Myal Y. Real-time PCR complements immunohistochemistry in the determination of HER-2/neu status in breast cancer. BMC Clin Pathol 2006;6:2.
6. Bilous M, Ades C, Armes J, et al. Predicting the HER2 status of breast cancer from basic histopathology data: an analysis of 1500 breast cancers as part of the HER2000 International Study. Breast 2003;12:92-8.
7. Slamon DJ, Clark GM, Wong SG, et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987;235:177-82.
8. Leyland JB, Trastuzumab: hope and realities. Lancet Oncol 2002;3:137-44.
9. Albanell J, Codony J, Rovira A, Mellado B, Gascón P. Mechanism of action of anti-HER2 monoclonal antibodies: scientific update on trastuzumab and 2C4. Adv Exp Med Biol 2003;532:253-68.
10. Kute T, Lack CM, Willingham M, et al. Development of Herceptin resistance in breast cancer cells. Cytometry A 2004;57:86-93.
11. Slamon DJ, Leyland JB, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001;344:783-92.
12. Abarca J. Assessing pharmacoeconomic studies In: Bootman JL, Townsend RJ, McGhan WF, eds. Principles of pharmacoeconomics. 3rd ed. Cincinnati, OH: Harvey Whitney Books Company, 2004:363-74.
13. Sanchez LA. Evaluating the quality of published pharmacoeconomic evaluations. Hosp Pharm 1995;30:146-8.
14. Neumann PJ, Stone PW, Chapman SM, Sandberg EA, Bell CM. The quality of reporting in published cost-utility analyses, 1976-1997. Ann Intern Med 2000;132:964-72.
15. Sculphur M, Fenwick E, Claxton K. Assessing quality indecision analytic cost-effectiveness models. A suggested framework and example of application. Pharmacoeconomics 2000;17:461-77.
16. Laupacis A, Feeny D, Detsky AS, Tugwell PX. How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations. CMAJ 1992;146:473-81.
17. Evans C, Tavakoli M, Crawford B. Use of quality adjusted life years and life years gained as benchmarks in economic evaluations: a critical appraisal. Health Care Manage Sci 2004;7:43-9.
18. Eichler HG, Kong SX, Gerth WC, Mavros P, Jonsson B. Use of cost-effectiveness analysis in health-care resource allocation decision-making: how are cost-effectiveness thresholds expected to emerge? Value Health 2004;7:518-28.
19. Lidgren M, Jonsson B, Rehnberg C, Willking N, Bergh J. Cost-effectiveness of HER2 testing and 1-year adjuvant trastuzumab therapy for early breast cancer. Ann Oncol 2008;19:487-95.
20. Dedes KJ, Szucs TD, Imesch P, Fedier A, Fehr MK, Fink D. Cost-effectiveness of trastuzumab in the adjuvant treatment of early breast cancer: a model-based analysis of the HERA and FinHer trial. Ann Oncol 2008;19:487-95.
21. Neyt MJ, Albrecht JA, Clarysse B, Cocquyt VF. Cost-effectiveness of Herceptin: a standard cost model for breast-cancer treatment in a Belgian university hospital. Int J Technol Assess Health Care 2005;21:132-7.
22. Millar JA, Millward MJ. Cost effectiveness of trastuzumab in the adjuvant treatment of early breast cancer: a lifetime model. Pharmacoeconomics 2007;25:429-42.
23. Norum J, Olsen JA, Wist EA, Lønning PE. Trastuzumab in adjuvant breast cancer therapy. A model based cost-effectiveness analysis. Acta Oncol 2007;46:153-64.
24. Kurian AW, Thompson RN, Gaw AF, Arai S, Ortiz R, Garber AM. A cost-effectiveness analysis of adjuvant trastuzumab regimens in early HER2/neu-positive breast cancer. J Clin Oncol 2007;25:634-41.
25. Liberato NL, Marchetti M, Barosi G. Cost effectiveness of adjuvant trastuzumab in human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol 2007;25:625-33.
26. Garrison LP Jr, Lubeck D, Lalla D, Paton V, Dueck A, Perez EA. Cost-effectiveness analysis of trastuzumab in the adjuvant setting for treatment of HER2-positive breast cancer. Cancer 2007;100:489-98.
27. Neyt M, Huybrechts M, Hulstaert F, Vrijens F, Ramaekers D. Trastuzumab in early stage breast cancer: a cost-effectiveness analysis for Belgium. Health Policy 2008;87:146-59.
28. Orlewaka E, Pienkowski T, Drosikn K, et al. Cost-effectiveness analysis of adjuvant therapy with trastuzumab for HER2-positive early breast cancer in Polish setting (abstract). Value Health 2007;10:A125.
29. Van Vlaenderen, Canon J, Cocquyt V, et al. Adjuvant trastuzumab treatment in early stage breast cancer : cost-effectiveness in the Belgian health care setting (abstract). Health in Value 2007;10:A336.
30. Chao TY, Chen SC, Chang KJ, et al. Cost-effectiveness analysis of adjuvant trastuzumab for HER-2 positive early breast cancer in Taiwan (abstract). Value in Health 2007;10:A327.
31. Correa M, Perdicaris M, Vernaglia PRW, et al. Cost-effectiveness analysis of trastuzumab therapy in patients with early HER-2 positive breast cancer in Brazil (abstract). Value Health 2007;10:A327.
32. Bell CM, Urbach DR, Ray JG, Bayoumi A, et al. Bias in published cost effectiveness studies: systematic review. BMJ 2006;332:699-703.
33. Ward S, Lloyd Jones M, Pandor A, et al. A systematic review and economic evaluation of statins for the prevention of coronary events. Health Technol Asses 2007;11:1-160.
34. Stevenson M, Jones ML, De Nigris E, Brewer N, Davis S, Oakley J. A systematic review and economic evaluation of alendronate, etidronate, risedronate, raloxifene and teriparatide for the prevention and treatment of postmenopausal osteoporosis. Health Technol Assess 2005;9:1-160.
35. Talmor D, Shapiro N, Greenberg D, Stone PW, Neumann PJ. When is critical care medicine cost-effective? A systematic review of the cost-effectiveness literature. Crit Care Med 2006;34:2738-47.